Bio-Techne
Where Science Intersects Innovation™
Hybrid
Some members of the team work remotely, while others are co-located in one or more offices.
👥1,001-5,000
📍Minneapolis, MN
Bio-Techne

About Bio-Techne

About Bio-Techne
About Bio-Techne
About Bio-Techne
About Bio-Techne
About Bio-Techne
Bio-Techne is a supplier of high quality and innovative tools for Life Science Research, Therapeutic Manufacturing and Clinical Diagnostics.

What Bio-Techne is building

Bio-Techne product / service
Bio-Techne product / service
Bio-Techne product / service
Bio-Techne product / service
Bio-Techne product / service
Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Technologies used at Bio-Techne

Back-end (4)
Front-end (2)
C#C#
SQLSQL
PythonPython
C++C++

Company culture

Empowerment

Releasing potential. Developing people. Providing the right tools.

Passion

Giving it everything. Making it enjoyable. Knowing why your work is important.

See more

Funding roundsIconOpenNewWindows

Company type

Company type

For Profit

Bio-Techne news and updates

Bio-Techne launched MitoBrilliant probes on Dec 5th 22'.

Bio-Techne Corporation (NASDAQ: TECH ) today announced the introduction of MitoBrilliant ™ probes.

Dec 5, 2022 | prnewswire.com

Bio-Techne launches TSA Vivid Fluorophores

MINNEAPOLIS, Oct. 12, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today announced the introduction of 3 novel TSA Vivid Fluorophores for highly sensitive fluorescent detection of RNAs and proteins in cells and tissues.

Oct 12, 2022 | prnewswire.com

Bio-Techne launched Simple Plex AAV2 assay in co-operation on Oct 11th 21'.

Bio-Techne introduced the Simple Plex AAV2 assay in co-operation with PROGEN last year, the first in its series of AAV assays for the reliable quantification of AAV capsid titers.

Oct 10, 2022 | instrumentbusinessoutlook.com

Bio-Techne launched medium ExCellerate IpsC expansion medium on Sep 1st 21'.

In September 2021, Bio-Techne Corporation developed a new medium ExCellerate IpsC expansion medium, for IpsC research in regenerative medicine.

Sep 28, 2022 | reportedtimes.com

Bio-Techne partners with Thermo Fisher Scientific

Bio-Techne Corporation has announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.

Feb 23, 2022 | biospectrumindia.com

Bio-Techne Corporation partnered with Thermo Fisher Scientific on Feb 22nd 22'.

Bio-Techne Corporation (NASDAQ: TECH ) today announced an agreement with Thermo Fisher Scientific to exclusively complete development of and commercialize the ExoTRU kidney transplant rejection test developed by Exosome Diagnostics, a Bio-Techne brand.

Jan 1, 2022 | prnewswire.com

ProteinSimple merges with Bio-Techne

ProteinSimple recently merged with Bio-Techne, and is now a part of the company’s Protein Platforms division.

Jan 1, 2022 | excedr.com

Bio-Techne partnered with Elpiscience Biopharmaceuticals on Jan 1st 20'.

Similarly, in 2020, Bio-Techne Corporation partnered with Elpiscience BioPharma with the objective of advancing anticancer therapeutics.

Jan 1, 2022 | themobility.club

Bio-Techne launched SARS-CoV-2 multi-antigen module for Simple Western on Oct 1st 20'.

For instance, Bio-Techne Corporation, in October 2020, launched a SARS-CoV-2 multi-antigen module for Simple Western and Jess automated western blotting systems.

Jan 1, 2022 | riponcollegedays.com

Bio-Techne recognized as Best Employers for Diversity 2022 on Apr 26th 22'.

Bio-Techne Corporation (NASDAQ: TECH) today announced that it has been included on the Forbes list of Best Employers for Diversity 2022.

Jan 1, 2022 | bio-techne.com

Bio-Techne launched Simple Plex HEK 293 HCP 3G assay for automated process impurity testing on the Ella immunoassay platform on Apr 12th 22'.

Bio-Techne Corporation (NASDAQ: TECH ) and Cygnus Technologies, part of Maravai LifeSciences (NASDAQ: MRVI ), announced today the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immunoassay platform.

Jan 1, 2022 | prnewswire.com

Bio-Techne receives award two important awards

On the human capital front, Bio-Techne received two important awards during the third quarter.

Jan 1, 2022 | seekingalpha.com

Bio-Techne hired Charles Kummeth as President and Chief Executive Officer on Apr 1st 13'.

Charles Kummeth became President and Chief Executive Officer of Bio-Techne Corporation on April 1, 2013.

Jan 1, 2022 | twst.com

Bio-Techne acquired Namocell Inc. on Jun 22nd 22'.

Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced it has reached an agreement to acquire Namocell, Inc.

Jan 1, 2022 | bio-techne.com

Bio-Techne launches Abby automated western system Bio-Techne

Bio-Techne launches Abby automated western system Bio-Techne announced that its brand ProteinSimple has released Abby, its next-generation chemiluminescence system that automates traditional western blotting.

Jan 1, 2021 | scienceboard.net

Morgan Stanley invests into Bio-Techne

New York-based Morgan Stanley has invested 0.01% in Bio-Techne Corporation (NASDAQ:TECH).

Jan 1, 2018 | whatsonthorold.com

Bio-Techne acquires Exosome Diagnostics for $250M

Bio-Techne has agreed to buy Exosome Diagnostics, a Massachusetts company whose technology tests for disease by scanning body fluids, for $250 million in cash.

Jan 1, 2018 | bizjournals.com
See More